Agentix Corp.: Business Overview, Financials & Competitive Analysis
Agentix Corp is a biotechnology company engaged in developing novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company's principal b...
Cyborg Score thesis
High-risk preclinical biotech with unproven endocannabinoid therapeutics competing against established pharma players; suitable...
Read the full analyst-debate transcript →Get the Latest Agentix Corp. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAgentix Corp. Overview
Pro stress-test →Agentix Corp is a biotechnology company engaged in developing novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company's principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and drive innovations in the endocannabinoid space.
Strategic Profile
Pro stress-test →The company is focused on developing synthetic agonists, inverse agonists, and antagonists which modulate the endocannabinoid system (ECS). Its pipeline includes AGTX-2004, a CB1 receptor antagonist demonstrated efficacy in animal models of obesity and type 2 diabetes, and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist with efficacy in animal models of obesity and non-alcoholic fatty liver disease. The company is in clinical-stage development with limited near-term revenue visibility.
Competitive Landscape
Pro stress-test →Agentix competes in the metabolic disease and endocannabinoid therapeutic space against established pharmaceutical companies with robust pipelines and regulatory experience. Direct competitors include larger biotech and pharma companies developing CB1 modulators and obesity/diabetes treatments. The company's peripheral-acting CB1 approach attempts to differentiate from first-generation systemic cannabinoid compounds, though clinical validation remains early-stage.
Industry Context
Agentix Corp. operates in Pharmaceuticals.
Key facts
Founded: 2013 (incorporated); rebranded June 2019 · Headquarters: Dana Point, California, US · Employees: 0-1 reported · Revenue: Estimated <$5M (private development stage)